180 related articles for article (PubMed ID: 14692526)
21. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.
Wu L; Wang T; Gui W; Lin H; Xie K; Wang H; Gao T; Zhang X; Liu L; Han T; Tian Y; Hou L
Oncology; 2014; 87(1):40-7. PubMed ID: 24969158
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
25. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.
Johnson PW; Whelan J; Longhurst S; Stepniewska K; Matthews J; Amess J; Norton A; Rohatiner AZ; Lister TA
Br J Cancer; 1993 Apr; 67(4):792-7. PubMed ID: 8471438
[TBL] [Abstract][Full Text] [Related]
26. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
27. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma.
Wu JZ; Tian T; Huang Y; Liang JH; Miao Y; Wang L; Xu J; Qu XY; Fan L; Li JY; Xu W
Cancer Biomark; 2016 Jul; 17(2):205-12. PubMed ID: 27434288
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
29. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
32. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
33. Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma.
Avilés A; Narváez BR; Díaz-Maqueo JC; Guzmán R; Talavera A; García EL
Leuk Lymphoma; 1993 Mar; 9(4-5):377-80. PubMed ID: 7688627
[TBL] [Abstract][Full Text] [Related]
34. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
35. Pleural effusion in patients with non-Hodgkin's lymphoma: a case-controlled study.
Elis A; Blickstein D; Mulchanov I; Manor Y; Radnay J; Shapiro H; Lishner M
Cancer; 1998 Oct; 83(8):1607-11. PubMed ID: 9781955
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
37. CA 125 elevations in patients with malignant lymphomas.
Fehm T; Beck E; Valerius T; Gramatzki M; Jäger W
Tumour Biol; 1998; 19(4):283-9. PubMed ID: 9679739
[TBL] [Abstract][Full Text] [Related]
38. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
39. Early death in patients diagnosed with non-Hodgkin's lymphoma.
Bairey O; Bar-Natan M; Shpilberg O
Ann Hematol; 2013 Mar; 92(3):345-50. PubMed ID: 23161388
[TBL] [Abstract][Full Text] [Related]
40. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
